| Mar-2025 | Dec-2024 | Sep-2024 | Jun-2024 | Mar-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 3.28% | 3.28% | 3.28% | 3.28% | 3.28% |
Indian | 47.38% | 47.38% | 47.38% | 47.38% | 47.38% |
Total Promoter | - | - | - | - | - |
Institutions | 24.26% | 23.93% | 23.6% | 23.56% | 22.84% |
Non-Institutions | 24.5% | 24.83% | 25.16% | 25.17% | 25.89% |
Total Non-Promoter | 48.76% | 48.76% | 48.76% | 48.74% | 48.74% |
Custodian | 0.55% | 0.55% | 0.55% | 0.58% | 0.58% |
Total | 100% | 100% | 100% | 100% | 100% |
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
